See where CE marking supports device approvals across 25+ markets, including full reliance, abridged review, evidence acceptance, and remaining local steps.
Your CE Mark Is Worth More Than EU Market Access
CE marking under EU MDR (Regulation 2017/745) or EU IVDR (Regulation 2017/746) is one of the most recognized regulatory approvals globally. But the extent to which it helps you enter markets beyond the EU/EEA varies dramatically — from countries that will register your device based on CE certification alone, to countries where CE is noted but carries no regulatory weight.
This guide organizes 25+ countries by the mechanism through which they recognize or leverage your CE mark. Understanding these mechanisms is essential for building a regulatory market access strategy that maximizes the return on your CE marking investment.
The Four Mechanisms of CE Mark Recognition
| Mechanism | What It Means | Regulatory Shortcut |
|---|
| A. Full Reliance | CE certification alone (or with minimal local administrative steps) is sufficient for market access. No full local technical review. | Significant — weeks to months instead of 6–12+ months |
| B. Abridged / Expedited Review | CE certification qualifies you for a shortened review track, but the local authority still conducts its own assessment. | Moderate — 30–50% shorter review timeline |
| C. Evidence-Only Acceptance | CE technical documentation is accepted as supporting evidence, but you must still complete a full local submission and review process. | Limited — reduces documentation preparation burden, not review time |
| D. Reference-Only / No Regulatory Weight | CE mark is considered as background information but carries no legal shortcut. Full local review required regardless. | None — regulatory benefit is informational only |
Tier A: Full Reliance Pathway
These countries will register your device based primarily on CE certification, with minimal additional local steps.
A1. Switzerland
| Attribute | Detail |
|---|
| Regulatory Authority | Swissmedic |
| CE Mechanism | Switzerland has transposed EU MDR/IVDR into national law (MEDEV/MepV). CE-marked devices are automatically accepted. |
| What CE Gets You | Full market access. No separate Swiss conformity assessment required for CE-marked devices. |
| Local Steps Required | Swiss Authorized Representative (CH REP) mandatory. Swissdamed registration by July 1, 2026 (transition until December 31, 2026). |
| Key Reference | Federal Act on Medical Devices (Medizinproduktegesetz, SR 812.213) |
A2. Norway, Iceland, Liechtenstein (EEA/EFTA)
| Attribute | Detail |
|---|
| Regulatory Authority | National health authorities (e.g., Norwegian Medicines Agency / Statens legemiddelverk) |
| CE Mechanism | As EEA/EFTA members, these countries are part of the EU's single market for medical devices. CE marking has the same legal force as in EU member states. |
| What CE Gets You | Full market access. No additional registration beyond EUDAMED requirements. |
| Local Steps Required | Same as any EU member state — EUDAMED registration, local importer requirements. |
| Key Reference | EEA Agreement, Annex II — Technical barriers to trade |
A3. Turkey
| Attribute | Detail |
|---|
| Regulatory Authority | Turkish Medicines and Medical Devices Agency (TITCK) |
| CE Mechanism | Turkey has a Customs Union with the EU and has transposed EU medical device directives into domestic law. CE-marked devices are accepted under the mutual recognition framework. |
| What CE Gets You | Full market access for CE-marked devices. |
| Local Steps Required | Product registration with TITCK, local authorized representative, Turkish labeling. |
| Key Reference | Turkey Medical Device Regulation, aligned with EU MDD/MDR framework |
A4. Singapore (for certain classes)
| Attribute | Detail |
|---|
| Regulatory Authority | Health Sciences Authority (HSA) |
| CE Mechanism | HSA's Full, Abridged, and Expedited review routes. CE-marked devices from recognized reference markets (EU, US, Australia, Japan, Canada) qualify for Expedited or Abridged routes depending on risk class. |
| What CE Gets You | For Class B/C devices with CE mark from EU Notified Body: Abridged route (shorter review than Full). Class A devices are exempt from product registration but require a Dealer's Licence. |
| Local Steps Required | HSA application, local registrant (Singapore-based), product labeling review. |
| Timeline Reduction | Full route: 6–12 months. Abridged with CE: 4–9 months. Expedited/IBR (Immediate Based on Reliance): as fast as 2–4 months for devices approved by 2+ reference agencies. |
| Key Reference | Health Sciences Authority — Guidance on Medical Device Registration |
A5. Australia (for certain classes)
| Attribute | Detail |
|---|
| Regulatory Authority | Therapeutic Goods Administration (TGA) |
| CE Mechanism | TGA permits use of CE certificates issued under MDR/IVDR to support device approval as part of its regulatory reliance strategy. |
| What CE Gets You | Eligible for abridged conformity assessment — fewer documents to submit, reduced depth of TGA evaluation, potential reduction in assessment fees. |
| Local Steps Required | Australian sponsor mandatory. TGA application still required. Australian Register of Therapeutic Goods (ARTG) inclusion. |
| Key Reference | Therapeutic Goods Act 1989, TGA regulatory reliance framework |
A6. New Zealand
| Attribute | Detail |
|---|
| Regulatory Authority | Medsafe (New Zealand Medicines and Medical Devices Safety Authority) |
| CE Mechanism | Mutual Recognition Agreement (MRA) between the EU and New Zealand covers conformity assessment. CE-marked medical devices benefit from this MRA. |
| What CE Gets You | Streamlined market access under the MRA framework. |
| Local Steps Required | Product notification to Medsafe, New Zealand sponsor. |
| Key Reference | EU-New Zealand Mutual Recognition Agreement on Conformity Assessment |
A7. Israel
| Attribute | Detail |
|---|
| Regulatory Authority | AMAR (Israeli Medical Device Division, Ministry of Health) |
| CE Mechanism | AMAR accepts CE marking as a basis for registration because the EU is listed as a recognized country under Schedule 1 of Israel's Medical Equipment Law (2012). Israel does not have its own classification system and relies on the classification from recognized countries. |
| What CE Gets You | Registration based on CE certification. AMAR review focuses on local requirements rather than full technical assessment. |
| Local Steps Required | Israeli Registration Holder (IRH), AMAR application, Hebrew/Arabic labeling for home-use devices, Standards Institution of Israel (SII) approval for electrical devices. |
| Key Reference | Israel Medical Equipment Law, 5772-2012; AMAR registration procedures |
A8. Serbia
| Attribute | Detail |
|---|
| Regulatory Authority | Medicines and Medical Devices Agency of Serbia (ALIMS) |
| CE Mechanism | Serbia recognizes foreign market authorization evidence. As part of its EU accession process, Serbia is aligning with EU standards. CE mark is accepted provided the product meets Serbian technical regulatory requirements. |
| What CE Gets You | Documentation accepted to support evaluation. No formal reliance pathway yet, but CE-marked devices receive favorable treatment during registration. |
| Local Steps Required | ALIMS registration prior to market placement. Serbian legal representative. |
| Key Reference | Serbian Law on Medical Devices; ALIMS registration guidelines |
A9. Bosnia and Herzegovina
| Attribute | Detail |
|---|
| Regulatory Authority | Agency for Medicines and Medical Devices of Bosnia and Herzegovina (ALMBiH) |
| CE Mechanism | Bosnia and Herzegovina accepts and considers overseas market authorization evidence, particularly from the EU, as part of its device registration process. |
| What CE Gets You | CE certificate streamlines the registration evaluation. Products with CE marking receive favorable treatment. |
| Local Steps Required | ALMBiH registration, local representative. |
A10. Montenegro
| Attribute | Detail |
|---|
| Regulatory Authority | Agency for Medicines and Medical Devices of Montenegro (CInM) |
| CE Mechanism | Montenegro accepts CE-marked devices and recognizes EU market authorization evidence. CE certificate supports the registration evaluation. |
| What CE Gets You | Streamlined registration process with CE documentation as the primary evidence. |
| Local Steps Required | CInM registration, local representative. |
A11. North Macedonia
| Attribute | Detail |
|---|
| Regulatory Authority | Agency for Medicines and Medical Devices (MALMED) |
| CE Mechanism | North Macedonia is currently reforming its medical device regulations to align with EU standards as part of its EU accession process. CE certificate is accepted and considered as part of the device registration process. |
| What CE Gets You | CE documentation supports the evaluation. No formal regulatory reliance framework, but favorable treatment. |
| Local Steps Required | MALMED registration, local representative. |
A12. Albania
| Attribute | Detail |
|---|
| Regulatory Authority | National Agency for Medicines and Medical Devices (AKBPM) |
| CE Mechanism | Albania accepts CE marking as part of its EU-harmonization process. CE certificate supports device registration. |
| What CE Gets You | Evidence of conformity. CE-marked devices receive favorable treatment during registration review. |
| Local Steps Required | AKBPM registration, local representative. |
A13. Northern Ireland
| Attribute | Detail |
|---|
| Regulatory Authority | MHRA (under Northern Ireland Protocol) |
| CE Mechanism | Under the Northern Ireland Protocol, CE marking continues to be recognized in Northern Ireland. CE-marked devices can be placed on the Northern Ireland market. |
| What CE Gets You | Full market access to Northern Ireland. |
| Local Steps Required | Northern Ireland-based importer or responsible person. |
Recommended Reading
EU-Switzerland MRA Update 2026: What It Means for Medical Device Market Access
RegulatoryEU MDR / IVDR2026-06-09 · 11 min read
Tier B: Abridged / Expedited Review
These countries offer a shortened review track when you hold CE certification, but still conduct their own assessment.
B1. Saudi Arabia
| Attribute | Detail |
|---|
| Regulatory Authority | Saudi Food and Drug Authority (SFDA) |
| CE Mechanism | SFDA regulations draw heavily from EU MDR. CE certificate is typically part of the supportive documentation for MDMA (Medical Device Marketing Authorization) applications. |
| What CE Gets You | Expedited review pathway — 35 working days for MDMA review. CE certificate serves as primary evidence of conformity. Without CE, the review may be longer and require additional documentation. |
| Local Steps Required | SFDA-licensed Authorized Representative (AR), MDMA application via GHAD system, Arabic/English labeling, UDI compliance with Saudi UDI framework. |
| Timeline | 35 working days for MDMA. |
| Key Reference | SFDA MDS-REQ1 — Requirements for Medical Device Marketing Authorization |
B2. United Kingdom (Great Britain)
| Attribute | Detail |
|---|
| Regulatory Authority | MHRA |
| CE Mechanism | MHRA currently accepts CE-marked medical devices in Great Britain. CE recognition has been extended — currently accepted until at least June 2028 (or June 2030 depending on device). MHRA is considering indefinite acceptance of CE marks. |
| What CE Gets You | Market access to GB without UKCA marking. MHRA is also proposing an international reliance pathway for devices approved in Australia, Canada, and the USA. |
| Local Steps Required | UK Responsible Person (UKRP), UKCA marking (if not using CE recognition route), MHRA registration. |
| Key Reference | MHRA guidance on CE mark recognition; UK Medical Devices Regulations 2002 (as amended) |
B3. Malaysia
| Attribute | Detail |
|---|
| Regulatory Authority | Medical Device Authority (MDA) |
| CE Mechanism | MDA Circular Letter No. 1/2025 introduced a "verification" process for CE-marked devices. CE certification qualifies devices for streamlined conformity assessment. |
| What CE Gets You | Verification route — CE-marked devices can be registered more efficiently. Reduced documentation requirements compared to full assessment pathway. |
| Local Steps Required | MDA application, local authorized representative (Malaysian-licensed establishment), CSDT-format submission. |
| Timeline | Verification route: typically 3–6 months. Full route: 6–12 months. |
| Key Reference | MDA Circular Letter No. 1/2025; Medical Device Act 2012 (Act 737) |
B4. Philippines
| Attribute | Detail |
|---|
| Regulatory Authority | FDA Philippines — Center for Device Regulation, Radiation Health, and Research (CDRRHR) |
| CE Mechanism | Under ASEAN Medical Device Directive (AMDD) implementation (FDA Circular No. 2021-002), CE-marked devices may qualify for the ASEAN recognition pathway. |
| What CE Gets You | Potentially shortened review under ASEAN reliance framework. CE technical documentation supports the CSDT submission. |
| Local Steps Required | Philippine FDA registration, local authorized representative (LAR), CSDT-format dossier. |
| Key Reference | FDA Philippines Circular No. 2021-002; ASEAN Medical Device Directive |
B5. United Arab Emirates
| Attribute | Detail |
|---|
| Regulatory Authority | Emirates Drug Establishment (EDE) — replaced MOHAP effective January 2, 2025 under Federal Decree-Law No. 38/2024 |
| CE Mechanism | EDE recognizes CE marking for medical devices. CE-certified devices may qualify for expedited registration. |
| What CE Gets You | Shorter review timeline for CE-marked devices. CE certificate accepted as primary conformity evidence. |
| Local Steps Required | UAE-based agent/representative, EDE registration, Arabic labeling. |
| Key Reference | Federal Decree-Law No. 38/2024; EDE medical device registration guidance |
Tier C: Evidence-Only Acceptance
These countries accept CE technical documentation as supporting evidence, but you must still complete a full local submission and review process.
C1. Brazil (ANVISA)
| Attribute | Detail |
|---|
| Regulatory Authority | Agência Nacional de Vigilância Sanitária (ANVISA) |
| CE Mechanism | CE certificate is accepted as supporting documentation under RDC 751/2022. ANVISA considers CE marking as evidence of conformity but conducts its own technical review. |
| What CE Gets You | Documentation efficiency — you can reference your CE technical file and clinical evaluation. However, ANVISA still performs an independent review, especially for Class III and IV devices. |
| Local Steps Required | Brazil Registration Holder (BRH), ANVISA registration, BGMP certification for Class III/IV, possible INMETRO certification, Portuguese labeling. |
| Key Reference | ANVISA RDC 751/2022; RDC 830/2023 (IVDs) |
C2. Colombia (INVIMA)
| Attribute | Detail |
|---|
| Regulatory Authority | Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) |
| CE Mechanism | INVIMA accepts CE certificate and technical documentation as supporting evidence. A Certificate of Free Sale or Certificate to Foreign Government from the country of origin is required. CE mark demonstrates prior regulatory approval. |
| What CE Gets You | Supports the registration application. INVIMA may grant "uncontrolled" (automatic) approval for Class I/IIa devices with CE marking. Class IIb/III devices still undergo INVIMA review. |
| Local Steps Required | Colombian legal representative, INVIMA registration, Spanish labeling, CTD format submission. |
| Key Reference | INVIMA Decree 4725/2005; Colombian medical device regulations |
C3. Chile
| Attribute | Detail |
|---|
| Regulatory Authority | Instituto de Salud Pública (ISP) |
| CE Mechanism | ISP accepts CE certification as supporting evidence for device registration. CE technical documentation supports the application. |
| What CE Gets You | Evidence of prior regulatory approval. May support expedited processing. |
| Local Steps Required | ISP registration, Chilean legal representative. Registration is indefinite once obtained (no renewal). |
| Key Reference | Chilean medical device regulations |
C4. Egypt
| Attribute | Detail |
|---|
| Regulatory Authority | Egyptian Drug Authority (EDA) |
| CE Mechanism | EDA references EU MDR classification and accepts CE certificates as part of the registration dossier. CE certificate is listed as a key document in the registration application. |
| What CE Gets You | Evidence of conformity. EDA classification generally references EU MDR risk classes. CE technical file supports the submission. |
| Local Steps Required | Egyptian Registration Holder (ERH), EDA registration (4–9 months), Arabic/English labeling. |
| Key Reference | EDA medical device registration guidance |
C5. Peru
| Attribute | Detail |
|---|
| Regulatory Authority | Dirección General de Insumos, Drogas y Medicamentos (DIGEMID) |
| CE Mechanism | DIGEMID accepts CE certificate as supporting evidence for device registration. |
| What CE Gets You | Evidence of prior regulatory approval. Supports the registration application. |
| Local Steps Required | DIGEMID registration, Peruvian legal representative, 5-year registration validity. |
| Key Reference | Peruvian medical device regulations |
C6. Thailand
| Attribute | Detail |
|---|
| Regulatory Authority | Thai Food and Drug Administration (Thai FDA) |
| CE Mechanism | Thai FDA accepts CE technical documentation under the CSDT format. CE certificate supports the application for Class 2–4 devices. |
| What CE Gets You | Documentation reuse — your CE technical file, clinical evaluation, and risk management file can be adapted for the CSDT submission. |
| Local Steps Required | Thai FDA registration, local authorized representative, establishment license, CSDT format submission. |
| Key Reference | Thai Medical Device Act B.E. 2551 (2008); ASEAN CSDT guidelines |
C7. Indonesia
| Attribute | Detail |
|---|
| Regulatory Authority | Ministry of Health (Kemenkes) / BPOM |
| CE Mechanism | Indonesia conducts its own review regardless of CE/FDA status. CE documentation is accepted as supporting evidence but does not replace local requirements. |
| What CE Gets You | Documentation reuse for the AKD (Alat Kesehatan — medical device) registration. CE technical file can be adapted, but Indonesia-specific requirements must be addressed. |
| Local Steps Required | AKD registration, local distributor with CDAKB compliance, Indonesian labeling, possible halal certification. |
| Key Reference | Indonesian Ministry of Health medical device regulations |
C8. Vietnam
| Attribute | Detail |
|---|
| Regulatory Authority | Ministry of Health (MOH) / Department of Medical Equipment and Construction (DMEC) |
| CE Mechanism | Vietnam broadly recognizes reference agency approvals. CE certification supports the registration application, particularly for Class B/C/D devices. |
| What CE Gets You | Class A/B: Registration in as fast as 7 days with reference approval evidence. Class C/D: Streamlined review with CE supporting documentation. |
| Local Steps Required | Vietnamese registration holder, MOH application, Vietnamese labeling. |
| Key Reference | Vietnam Law on Medical Devices; MOH Circular 08/2023/TT-BYT |
Tier D: Reference-Only / No Regulatory Weight
These countries are aware of CE marking but it provides no formal regulatory shortcut. Full local review is required regardless.
D1. China (NMPA)
| Attribute | Detail |
|---|
| Regulatory Authority | National Medical Products Administration (NMPA) |
| CE Status | CE certification has no formal regulatory weight in China. NMPA requires a full domestic registration process for Class II and III devices. |
| What This Means | You cannot leverage your CE certificate to skip or shorten NMPA registration. Full NMPA type testing (at a Chinese laboratory), clinical data (possibly Chinese clinical trials), and NMPA technical review are required. |
| Key Reference | China Order No. 739 — Regulations on the Supervision and Administration of Medical Devices |
D2. Russia (Roszdravnadzor)
| Attribute | Detail |
|---|
| Regulatory Authority | Federal Service for Surveillance in Healthcare (Roszdravnadzor) |
| CE Status | CE marking is considered but carries no formal regulatory shortcut. Russia requires its own registration certificate (RU) for all medical devices. |
| What This Means | Full Russian registration process required, including possible local testing, Russian-language documentation, and Roszdravnadzor review. |
| Key Reference | Federal Law No. 323-FZ on Fundamentals of Protecting the Health of Citizens |
D3. India (CDSCO)
| Attribute | Detail |
|---|
| Regulatory Authority | Central Drugs Standard Control Organization (CDSCO) |
| CE Status | CE certificate is referenced but does not provide a formal regulatory shortcut. CDSCO requires full import license (MD-14/MD-15) process. |
| What This Means | Full CDSCO application, Indian Authorized Agent, SUGAM portal submission. BIS certification required for electronic medical devices. |
| Key Reference | Medical Devices Rules (MDR) 2017 |
D4. Japan (PMDA)
| Attribute | Detail |
|---|
| Regulatory Authority | Pharmaceuticals and Medical Devices Agency (PMDA) |
| CE Status | CE marking has no formal regulatory weight. Japan has its own comprehensive regulatory framework (Todokede/Ninsho/Shonin pathways). |
| What This Means | Full PMDA registration required: MHLW Ordinance No. 169 QMS compliance, Designated Marketing Authorization Holder (DMAH/MAH), Foreign Manufacturer Registration (FMR). All documents in Japanese. |
| Key Reference | Pharmaceuticals and Medical Devices Act (PMD Act) |
D5. South Korea (MFDS)
| Attribute | Detail |
|---|
| Regulatory Authority | Ministry of Food and Drug Safety (MFDS) |
| CE Status | CE marking is referenced but does not provide a formal shortcut. MFDS requires Korean GMP (KGMP) certification, which is separate from ISO 13485. |
| What This Means | Full MFDS registration: notification/certification/approval pathway, KGMP audit, Korea License Holder (KLH). |
| Key Reference | Medical Devices Act (South Korea) |
D6. Canada (Health Canada)
| Attribute | Detail |
|---|
| Regulatory Authority | Health Canada |
| CE Status | Health Canada does not formally recognize CE marking. Canada has its own Medical Device Regulations (MDR) under the Food and Drugs Act. |
| What This Means | Full Health Canada application, MDSAP certification, Medical Device License (MDL) application. |
| Key Reference | Canada Food and Drugs Act; Medical Device Regulations (SOR/98-282) |
D7. Mexico (COFEPRIS) — Fast-Track Available with CE
| Attribute | Detail |
|---|
| Regulatory Authority | Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) |
| CE Status | COFEPRIS offers a 30-day fast-track (aprobación automática) for devices with FDA or CE approval under Article 376 of the Mexican General Health Law. This is effectively a Tier B (abridged review) pathway for CE-marked devices. Mexico is listed in Tier D because full local registration is still required — the fast-track shortens but does not eliminate the COFEPRIS review. |
| What This Means | With CE certificate, you may qualify for the fast-track pathway (approximately 30 working days). Without it, standard pathway takes 3–6 months. |
| Key Reference | COFEPRIS medical device registration guidelines; Article 376 compliance requirements |
D8. Argentina (ANMAT)
| Attribute | Detail |
|---|
| Regulatory Authority | Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) |
| CE Status | CE certificate is considered as reference information. Full ANMAT registration is required. |
| What This Means | Full registration process: 6–12 months, Argentine legal representative. |
| Key Reference | ANMAT Disposición 3567/2011 and subsequent updates |
Recommended Reading
EClinCloud EDC for Device Studies: Linking Versions, Deficiencies and Endpoints
Clinical EvidenceRegulatory2026-09-07 · 35 min read
Strategic Summary: The CE Mark Value Matrix
| Country | Tier | CE Benefit | Additional Local Steps | Effective Time Savings |
|---|
| Switzerland | A | Full access | CH REP, Swissdamed | Complete — no additional conformity assessment |
| Norway/Iceland/Liechtenstein | A | Full access | EUDAMED registration | Complete — part of single market |
| Turkey | A | Full access | TITCK registration, local rep | Complete — mutual recognition |
| Singapore | A | Abridged/IBR review | HSA application, local registrant | 25–50% time savings (abridged); up to 60% (IBR with 2+ ref approvals) |
| Australia | A | Abridged assessment | TGA application, Australian sponsor | 30–50% time savings |
| New Zealand | A | Streamlined under MRA | Medsafe notification, NZ sponsor | Significant under MRA |
| Israel | A | Registration basis | AMAR application, local importer | Significant — MRA-based |
| Serbia | A/B | CE accepted, favorable treatment | ALIMS registration, local rep | Documentation efficiency |
| Bosnia and Herzegovina | A/B | CE recognized, streamlined | ALMBiH registration, local rep | Documentation efficiency |
| Montenegro | A/B | CE recognized, streamlined | CInM registration, local rep | Documentation efficiency |
| North Macedonia | A/B | CE considered during EU alignment | MALMED registration, local rep | Documentation efficiency |
| Albania | A/B | CE accepted during EU alignment | AKBPM registration, local rep | Documentation efficiency |
| Saudi Arabia | B | Expedited MDMA review | SFDA AR, GHAD application | 35-day review vs. longer without CE |
| United Kingdom (GB) | B | CE recognition (until 2028/2030) | UKRP, MHRA registration | Avoids UKCA process |
| Malaysia | B | Verification route | MDA application, local rep | 3–6 months vs. 6–12 months |
| UAE | B | Expedited registration | EDE registration, local agent | Shorter timeline with CE |
| Philippines | B | ASEAN recognition pathway | FDA registration, local rep | Shortened under AMDD |
| Brazil | C | Supporting evidence | BRH, ANVISA review, BGMP | Documentation efficiency only |
| Colombia | C | Supporting evidence | INVIMA registration, local rep | May enable automatic approval for low-risk |
| Egypt | C | Supporting evidence | ERH, EDA registration | Documentation efficiency |
| Thailand | C | Documentation reuse | Thai FDA, CSDT format | Documentation efficiency |
| Indonesia | C | Documentation reuse | AKD registration, local distributor | Documentation efficiency |
| Vietnam | C | Reference evidence | MOH registration, local holder | 7-day fast-track for Class A/B |
| China | D | No regulatory weight | Full NMPA process | None |
| Russia | D | No regulatory weight | Full Roszdravnadzor process | None |
| India | D | No regulatory weight | Full CDSCO process | None |
| Japan | D | No regulatory weight | Full PMDA process | None |
| South Korea | D | No regulatory weight | Full MFDS process | None |
| Canada | D | No regulatory weight | Full Health Canada process | None |
| Mexico | B/D | Fast-track available | COFEPRIS 30-day track if CE/FDA | 30 days vs. 3–6 months |
How to Use This Map in Your Regulatory Strategy
Start with Tier A countries. If you hold CE marking, you should immediately register in Switzerland (Swissdamed), Turkey (TITCK), Singapore (HSA), Australia (TGA), New Zealand (Medsafe), and Israel (AMAR). These markets offer the highest return on your CE investment with the lowest incremental regulatory cost.
Add Tier B countries in your next wave. Saudi Arabia, UK, Malaysia, and the Philippines offer meaningful time savings. Factor the local representative appointment and application preparation into your market access timeline.
Use Tier C for portfolio-level expansion. For markets like Brazil, Colombia, Egypt, Thailand, and Vietnam, your CE technical documentation reduces preparation time but does not shorten the regulatory review. Plan these as medium-term market entries.
Treat Tier D as standalone registrations. China, Japan, India, and South Korea require fully independent registration strategies. Do not budget time savings from CE marking into your plans for these markets.
Combine CE with FDA approval for maximum leverage. Holding both CE mark and FDA 510(k) or PMA approval unlocks additional pathways — COFEPRIS fast-track in Mexico, enhanced credibility in Tier C markets, and dual-reference advantages across ASEAN and LATAM.
Key References
EU MDR Regulation (EU) 2017/745 — Annex VIII classification rules
EU IVDR Regulation (EU) 2017/746
RQM+ — "Where can your CE mark take you next?" (2026)
European Commission — List of Mutual Recognition Agreements
HSA Singapore — Guidance on Medical Device Registration
TGA Australia — Regulatory reliance framework
SFDA Saudi Arabia — MDS-REQ1
MHRA UK — CE mark recognition guidance
MDA Malaysia — Circular Letter No. 1/2025
ANVISA Brazil — RDC 751/2022
EDA Egypt — Medical device registration guidance
Swissmedic — Swissdamed registration obligations 2026
